An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Description: 
In subjects with previously untreated stage IV or recurrent PD-L1+ NSCLC:To compare the overall survival of nivolumab monotherapy and nivolumab in combination with ipilimumab to platinum-doublet chemotherapy To compare progression-free survival based on blinded independent central review (BICR) assessment, of nivolumab monotherapy and nivolumab in combination with Ipilimumab to platinum-doublet chemotherapy In subjects with previously untreated stage IV or recurrent PD-L1- NSCLC:To compare the overall survival of nivolumab in combination with ipilimumab to platinum-doublet chemotherapy To compare progression-free survival based on BICR assessment, of nivolumab in combination with ipilimumab to platinum-doublet chemotherapy
Study Number: 

PH 271415

Phase: 
3
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02477826

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.